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SummAry 
Purpose: to assess the safety and efficacy of changing antiglaucoma therapy to the travoprost 
0,004%/timolol 0,5% (ttfC) fixed combination from previous monotherapies.
Methods: Prospective, open-label, observational, multicenter cohort. A change was done from 
prior monotherapy at day 0 to ttfC dosed once a day, regardless in the evening or in the morning, 
without washout period. Active evaluation of systemic and local tolerability (adverse events), and 
efficacy ie. intraocular pressure (iOP) lowering was done at control 1 (day 30), control 2 (day 90) and 
control 3 (day 120). 
Results: 40/155/170 patients (79/309/339 eyes) completed the study (120 days/ 90 days/baseli-
ne, respectfully). At control 1 excluded were patients with low tolerability (severe hyperemia (6 pati-
ents), discomfort (4), chest pain (1)) and non responders (iOP lowering less than 15% from baseline 
iOP or target iOP >18 mmhg (4 patients)). 
mean iOP at control 1 was 15,92±1,85 mm hg (21,66% reduction) for 155 patients (non res-
ponders excluded), at control 2 was for 155 patients 15,67±2,17 mm hg (21,14% reduction), and at 
control 3 for 40 patients 16,28±1,59 mm hg (19,86% reduction).
At control 2 analysis of iOP reduction by 4 groups of previous monotherapy (timolol 0,5% 
(n=33/66), latanoprost 0,005% (n=49/98), betaxolol 0,5% (n=30/60), and travoprost 0,004% 
(n=43/85) was performed. 
Author for correspodence: Katia novak lauš, md, Phd, department of Ophthalmology, 
Clinical hospital Sisters of Charity, vinogradska cesta 29, 10 000 Zagreb, Croatia
e-mail: katianl@net4u. hr
The procedures followed were in accordance with the ethical standards of the institutional or regional responsible committee on human 
experimentation and with the helsinki declaration of 1975, as revised in 1983.
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40 patients/79 eyes endured to control 3 (after day 90 free samples were not available for all pa-
tients). Analysis of iOP reduction by 4 groups of previous monotherapy medications was performed 
(timolol 0,5%(n=7/14), latanoprost 0,005% (n=14/28), betaxolol 0,5% (n=7/14),  travoprost 0,004%  
(n=12/23)). 
Conclusions: Changing patients from prior monotherapy to ttfC can provide on average a 
further reduction in iOP, while demonstrating a favorable safety profile.
Key words: Glaucoma – drug therapy; Ocular hypertension – drug therapy; Intraocular pressure – drug 
effects; Antihypertensive agents – administration and dosage; Drug combinations
Introduction 
glaucoma is a group of ocular diseases character-
ized by optic nerve damage and visual field loss. while 
the precise pathophysiology is unknown, the end re-
sult of glaucoma is retinal ganglion cell death. exten-
sive optic nerve injury and visual field loss often have 
already occurred by the time of diagnosis. Although 
some glaucoma patients have normal intraocular pres-
sure (iOP), glaucomatous injury is highly correlated 
with increased iOP. Therefore, reducing iOP is a 
mainstay of glaucoma therapy.
There are several different classes of glaucoma 
medications available today (prostaglandin analogues 
and β blockers among them).
travoprost is a prostaglandin analogue and a very 
selective agonist for the prostaglandin fP receptor1. it 
lowers the iOP in patients with primary open angle 
glaucoma (POAg) and/or ocular hypertension (Oh), 
in cases intolerant or insufficiently responsive to other 
iOP-reducing medications. it is believed that travo-
prost reduces iOP by increasing the outflow of aque-
ous humor through the uveoscleral drainage route, and 
possibly even with trabecular meshwork resistance re-
ducing2-5. it provides effective reductions in iOP with 
once daily dose, applied in the evening6,7. it has been 
showed that travoprost produces an additional reduc-
tion in iOP when used in combination with topical 
ophthalmic beta blocker timolol8. 
beta-blockers have a role in reducing iOP level by 
slowing the rate of aqueous humor formation9,10. These 
two complementary modes of action are used together 
in a fixed combination of two drugs. timolol is often 
used twice a day in the treatment of POAg and Oh. 
On the other hand, the use of a fixed combination 
of beta-blocker timolol and prostaglandin analogue in 
a single ophthalmic solution is provided once daily, 
with a significant additive effect11, also improving pa-
tient compliance. 
until introduction of fixed combination travoprost 
0,004%/timolol 0,5% (ttfC), in Croatia were com-
monly used unfixed combinations of those two groups 
of medications in glaucoma therapy. 
This observational, non interventional, open – la-
bel multicenter study was designed to evaluate chang-
es in pattern of glaucoma medications prescription of 
majority of our glaucoma specialists, once this ttfC 
available in Croatia. 
The ophthalmic solution  ttfC was prescribed 
as replacement for previous medication, as judged by 
investigator, and was applied once daily in the evening 
or in the morning during a period od 6 months with-
out washout period when the change was done. we 
observed wether ttfC provides sufficient iOP con-
trol (further reduction from baseline) and observed 
tolerability of new medication in patients with POAg 
and Oh. 
Methods
in this study included were patients with previous 
diagnosis of POAg or Oh, who required a change 
of previous glaucoma medications therapy according 
to each investigator criteria from ten glaucoma dep-
ertments distributed equally throughout Croatia ( 5 
in Zagreb,  and 1 in Osijek, Split, rijeka, Zadar and 
Šibenik, respectfully). included were patients of  both 
gender (43.2% male, 56.8% female), all caucasian, 
older than 18 years, whose iOP was not adequately 
controlled or who were intolerant to previous iOP 
lowering medications. definition of adequacy in iOP 
control was previously determined by consensus: in-
cluded were patients with iOP at baseline (achieved 
with any of monotherapies) between 19-35 mmhg in 
at least one eye(safety resons for 35 mmhg).
The exclusion criteria were determined in accor-
dance with product labeling (contraindications and 
possibly pregnant / pregnant women). visual acuity, 
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cup/disc ratio, grade of angle closure were recorded, 
but not corellated to iOP measurement lately. All 
patients were given informed consent. All investiga-
tors had prior the inclusion to the protocol written 
aprooval of ethical boards at each site. An analysis 
of changes in cardiovascular parameters (pulse rate, 
systolic blood pressure and diastolic blood pressure) 
has been performed in order to detect systemic ad-
verse events of both beta blocker anf prostaglandin 
analogue component at the control 1  and controls1, 
2 and 3 (these findings were not corellated with iOP 
changes). no further laboratory measurements were 
performed in order to detect systemic adverse events.
Participants were grouped into four categories ac-
cording to previous monotherapy:  those on timolol 
0,5%, those on betaxolol 0,5%, those on latanoprost 
0,005%, those on  travoprost 0,004% .
Patients were given one drop of ttfC in the eve-
ning at 8 Pm or in the morning at 8 Am (accord-
ing to their preference /lifestyle), during a period of 
three to six months. no washout period from prior 
medications was employed because we were oblidged 
by authorities not to intervene in each of investiga-
tors practice, just observe pattern of efficacy and safety 
for the ttCf - mimicking daily clinical practice. All 
patients were given free samples for 90 days therapy. 
After that, samples free of charge were available only 
for 40 patients for another 30 days. ttfC combina-
tion was not reimbursed at that time, but was avail-
able in pharmacies in Croatia. Patients who were not 
included in follow up from day 90 to day 120 were 
instructed to continue with ttfC therapy.
main outcome measures included mean iOP and 
tolerability (adverse events) variables. 
iOP was measured at goldmann applanation 
tonometer for each eye between 9 Am and 11 Am at 
baseline (day 0) and at three control visits: control 1 ie. 
day 30, control 2 ie. day 90 and control 3 ie. day 120 
of ttfC therapy. in each patient, the eye with the 
higher baseline level of iOP was chosen for  analysis. 
in cases with equal iOP level in both eyes, the right 
eye iOP value was analised.
responder analysis was performed at day 30 (con-
trol 1) in order to exclude non responders. Consensus 
criteria for non responders was iOP reduction from 
baseline of 15% or achieved target iOP>18mmhg. An 
iOP of 18 mmhg was used as the ‘target iOP’ con-
sistent with the findings of the national eye institute 
sponsored Advanced glaucoma intervention Study 
(AgiS) which demonstrated that patients with iOP < 
18 mmhg at all visits over 6 years had mean changes 
from baseline in visual field score close to zero during 
follow-up.
Conjunctival hyperemia was evaluated according 
to 4 point scale (severe, mild, moderate, none) from 
CClru grading scale12.
The Kruskal wallis test was used for statistical 
analysis. A P-value of <0.05 was considered to be sta-
tistically significant. 
Results
Study included at baseline 170 patients / 339 eyes 
with POAg and Oh (43.2% male, 56.8% female; 
76% POAg cases and 24% of patients suffering from 
Oh) and with a similar distribution of adult and el-
derly(50.3% vs. 49.7%, respectively) patients. All the 
patients were Caucasian (100%) and majority had 
brown irides (50.9%).
Analysis was focused on the substitution of one of 
four common, antiglaucoma medications with ttfC. 
They included following groups: timolol 0,5% mono-
therapy (n=35), latanoprost 0,005%  monotherapy 
(n=54), betaxolol 0,5% monotherapy (n=36),  travo-
prost 0,004% monotherapy (n=45) at baseline.
IOP analysis
The main focus was change in iOP lowering in pa-
tients switched from their previous therapy to ttfC, 
measured at control visits 1 (day 30), 2 (day 90) and 3 
(day 120). 
At the first control visit, after 30 days of therapy, 
we recorded individual iOP in each eye in order to 
exclude non responders (iOP reduction from baseline 
for each eye less than 15% or not reached target iOP 
>18 mmhg). excluded because of criteria of unmet 
criteria of 15% iOP change from baseline were 4 pa-
tients (figure 1).
At the baseline visit, mean iOP was 22,1±2,87 mm 
hg (all medications/ all patients). At the control 1 (day 
30), mean iOP was 15,92±1,85 mm hg (reduction of 
21,66%). At the control 2 (day 90), the mean iOP was 
15,67±2,17 mm hg (reduction 21,14%) (figure 2). 
At the control 3 (day 120) mean iOP was 16,28±1,59 
mm hg (19,86% reduction) (figure 2). The  differ-
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ences (mean±standard deviation) in iOP after 30, 90 
and 120 days were all highly statistically significant 
(p<0,001) compared to baseline values.
in patients switched from timolol 0,5% the change 
in mean iOP at control 2 (90 days) was 5,2±2,7 mmhg, 
in betaxolol 0,5% group it was 5,7±2,2 mmhg, in la-
tanoprost 0,005% group it was 3,8±2,6 mmhg, in tra-
voprost 0,004% group 4,4±2,8 mmhg (figure 3). 
Change in mean iOP by all groups of medications 
at all control points is summarized in table 1, and is 
highly statistically significant (table 1).
in total 155 patients (309 eyes) survived the study 
until control 2 (90 days). At control 2 (day 90) excluded 
were patients who could not afford to buy ttfC (not 
reimbursed in Croatia, because free units of ttfC 
from donation were available for only 40 patients). 
until the end of the study endured 40 patients (79 
eyes).
in this group of 40  patients (79 eyes), monothera-
pies prior to the ttfC  substitution were as follows: 
timolol 0,5% (7 patients/14 eyes); betaxolol 0,5% (7 
patients/14 eyes); latanoprost 0,005% (14 patients/28 
eyes); travoprost 0,004% (13/23 eyes). measurement of 
mean change of iOP from baseline was performed for 
all survivors until day 120: it was for timolol 0,5 group 
3,85±0,88 mmhg, betaxolol 0,5% group 4,09±0,83 
mmhg, latanoprost 0,005% group 4,8±1,63 mmhg, 
travoprost 0,004% group 4,07±1,38 mmhg (figure 
4).
Tolerability (adverse events)
At control 1 excluded were from further follow up 
15 patients with adverse events (severe hyperemia in 
6 patients, discomfort of the eye in 4 patients, chest 
pain 1 in patient). reported were also mild hyperemia 
in 4 patients (8 eyes) after 30 days of ttfC therapy, 
but patients were highly motivated to continue with 
medication. After 90 days of therapy in those 4 pa-
tients hyperemia was not present any more. At control 
2 we also report eyelashes growth in 2 patients - 4 
eyes, they were not excluded, and all successfully fin-
ished the study.  





























Fig. 1. Responder analysis at control 1 (day 30): IOP change 
(mm Hg) for each eye from baseline (n=170 patients/ 339 
eyes). Four patients (8 eyes) were excluded based on unmet 
consensus criteria (IOP change by 15% from baseline or IOP 
>18 mm Hg). 
Fig. 2. Mean IOP (mm Hg) in all patients (day 0 and day 
30), survivors on day 90 (follow up 2) and survivors on day 
120 (follow up 3). Differences in the mean and standard de-




















 baseline control 1 control 2 control 3
 baseline Control 1 Control 2 Control 3 P*
betaxolol 20,92 ± 1,62 16,04 ± 0,94 16,21 ± 1,05 16,83 ± 0,83 < 0,001
latanoprost 21,07 ± 2,77 16,27 ± 1,94 15,90 ± 1,72 16,27 ± 1,63 < 0,001
timolol 21,46 ± 2,51 16,86 ± 1,15    17 ± 0,73 17,61 ± 0,88 < 0,001
travoprost 21,11 ± 1,28 17,07 ± 1,64 16,89 ± 1,30 17,04 ± 1,38 < 0,001
P** 0,901 0,059 0,009 0,005  
* friedman
** Kruskal wallis
Table 1. Mean IOP (mmHg) by groups of medications at baseline and control 1, 2 and 3.
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Discussion
new ttfC is more effective than any previously 
used medication (both monotherapy – betaxolol 0,5%, 
timolol 0,5%, latanoprost 0,005%, travoprost 0,004%) 
based on iOP lowering efficacy.
in our study ophthalmologists change medication 
when iOP is not sufficiently controlled or in case of 
glaucoma disease progression, according to personal 
clinical experience and european glaucoma Society 
guidelines.
Patients in this study, once compared to inter-
national (pivotal) studies13 react to medication with 
significant iOP lowering, with expected number of 
responders after 30 days of therapy and maintain ef-
ficient iOP control up to 120 days that we managed to 
follow up our cohort. 
The dropouts from the study were because of re-
ported adverse events (severe hyperemia in 6 patients, 
discomfort in 4 patients, chest pain 1 in patient), and 
were in range of expected from product labeling. 
exclusions were done by investigators according to 
consensus on iOP reduction of at least 15% or target 
iOP <18mmhg, necessary to qualify each patient for 
„responder“ group. number of responders is consis-
tant to reported in pivotal studies 6-8,13 .
Clinical studies have previously shown that the 
ttfC produced clinically relevant reduction of iOP, 
greater than those caused by either travoprost or 
timolol alone13. it has also been shown that the use 
of  ttfC provides safety and efficacy. The concomi-
tant use of both drugs has the same efficacy in iOP-
lowering 14-18. This study demonstrates that patients 
who underwent a change in therapeutic regimen from 
other antiglaucomatous therapeutics to ttfC consis-
tantly showed a further iOP reduction, regardless of 
which therapies had been previously used. This could 
be the consequence of enhanced patient compliance 
(due to once-a-day usage compared to twice per day 
timolol 0,5% and betaxolol 0,5%), as well as the pre-
dominant iOP reducing role of prostaglandins. Some 
studies have shown that travoprost has some pharma-
cologic differences compared to other prostaglandins. 
According to hellberg et al. 19 travoprost is a potent 
full agonist to the fP-receptor (emax = 100%) in com-
parison to latanoprost (emax = 75%).  Sit et al. 20 and 
dubiner et al. 21 have shown that travoprost exibits 
enduring iOP-lowering efficacy. On the other hand, 
in some patients, the effect of timolol shades away 
after a period of 24 hours. That provides better iOP 
control of ttfC comparing to other prostagladin/
timolol fixed combination, according to the endurance 
Fig. 3. IOP change (mm Hg) from baseline according 
to groups of previous medications at follow up 2 (day 90) 
(Kruskal Wallis analysis).
Fig. 4. IOP change (mm Hg) from baseline according to 
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of travoprost which compensates the waning effect of 
the timolol during the day.
results in iOP reduction and tolerability (adverse 
events) in this study follow up expected pattern from 
published pivotal and observational studies 22-24.
The mean iOP change after 3 months of therapy 
with ttfC in our study showed following: in group 
switched from timolol mean iOP reduction was 
5,2±2,7 mmhg, in latanoprost group it was 3,8±2,6 
mmhg, and in travoprost group 4,4±2,8 mmhg, in 
range of results in similar study by Arend et al. 22 . 
The difference from these studies was our analysis 
of aditional group of patients, previously treated by 
betaxolol, in which we found the mean iOP lower-
ing of 5,7±2,2 mmhg, while Arend et al. did not. 
barnabey et al. 13 found that the ttfC produced 
clinically relevant reductions in iOP that were greater 
than those produced by either travoprost or timolol 
alone. in Konstas et al. study23 the ttfC proved an 
aditional iOP reduction from baseline (mean 24 hour 
9,4 mmhg) compared to travoprost alone (7,1mmhg) 
after 3 months. Stewart et al. 25 proved a  signifi-
cant decrease in iOP 3 months after changing to 
ttfC regardless of prior therapy: travoprost 0,004% 
(16,3±2,4mmhg vs 22,0±2,3mmhg), timolol 0,5% 
(16,3±2,4 mmhg vs 21,8±2,1mmhg, latanoprost 
0,004% (16,8±2,3mmhg vs 22,0±2,3mmhg). in 
observational study Pfeiffer et al.24 performed at 474 
patients in germany found reduction of iOP after 3 
months of ttfC therapy 5,6±2,6 mmhg for all prior 
treatments (for timolol monotherapy 5,7±2,2 mmhg, 
for latanoprost monotherapy 6,3±2,6mmhg).
iOP lowering effect of ttfC in our study was 
superior in comparison to previous monotherapy 
with betaxolol, timolol 0,5%, latanoprost and travo-
prost 0,004%, during 6 months (120 days) period. 
mean reduction of iOP was 19,86% after 6 month of 
therapy.  not many studies report ttfC effective in 
longer period than 3 months 26-28, 13-16 and only two up 
to 12 months period 28,29,30. in rossi et al. 29 6 month 
multicenter, observational study on 309 patients iOP 
was significantly decreased (from 18.3 ± 2.9 to 16.6 ± 
2.7 mmhg) after substitution(p < 0.0001). 82% pa-
tients reached an iOP < 18 mmhg (p < 0.0001)29. in 
our study, at the control 3 (day 120) mean iOP was 
16,28±1,59 mm hg (19,86% reduction). in study of 
danesh mayee and topousis30 (and the trav/tim 
1-year Study group) ttCf was compared to previ-
ously administered latanoprost 0,005%/timolol0,5% 
fixed combination in order to test noninferiority in 
iOP lowering with new ttfC – iOP lowering ef-
fect was significant (compared to the baseline entry) 
at 6 months and endured to one year. furthermore, 
at 9:00 Am, 24 hours after dosing, iOP was statisti-
cally lower for travoprost 0.004%/timolol 0.5% pooled 
across all visits 30.
The differences (mean±standard deviation) in in-
traocular pressure values at baseline and after 30, 90 
and  120 days were all highly statistically significant 
(p<0,001). recent large clinical studies such as Ocular 
hypertension treatment Study (OhtS)31, the early 
manifest glaucoma trial (emgt)32, and AgiS33, 
have clearly indicated the significance of lowering 
iOP in preventing the development of open-angle 
glaucoma in susceptible individuals and the progres-
sion of visual field loss in those who already have 
the disease. ttfC  showed endurance of intraocu-
lar pressure  lowering effect  in current study during 
observed 6 months  period. This fixed combination 
product may, therefore, be of value in patients judged 
to be inadequately controlled on a prostaglandin ana-
logue or ophthalmic beta-blocker alone.
in current study ttfC was safe and well-toler-
ated.  As with any beta-adrenergic receptor blocking 
agent, adverse respiratory and cardiac reactions may 
occur with timolol. An analysis of changes in cardio-
vascular parameters (pulse rate, systolic blood pres-
sure and diastolic blood pressure) has been performed, 
the results of which are reassuring with no new or un-
expected safety concerns. One patient was excluded 
from the further follow up after 30 days of treatment 
with new ttfC, due to the chest pain complaint.
in his case no discrepancies were found in pulse rate, 
systolic or diastolic blood pressure. The complaint re-
solved with treatment discontinuation, withouth adi-
tional treatment.
Considering that travoprost and timolol are two 
distinct pharmacological agents, which act by differ-
ent mechanisms of action and the lack of interaction 
reports in the literature, support the view that the 
two agents do not impact significantly on the phar-
macodynamics of one another. reported side effects 
incidence and occurence is comparable to reported 
when those two agents used alone (travoprost 0,004% 
monotherapy or timolol 0,5% monotherapy)13.
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Ocular hyperemia, discomfort in the eye and pru-
ritus eye were the most common ocular adverse events 
reported in pivotal studies 13,14,15,16,17,18 , with incidences 
of 14.4%, 6.5% and 4.8% in ttfC, 20.8%, 9.9% and 
5.4% in travoprost plus timolol, 11.6%, 2.3% and 3.5% 
in travoprost, 1.7%, 5.7% and 2.3% in timolol and, 4%, 
3.6% and 2.5% in latanoprost/timolol  fixed combina-
tion treatment groups, respectively. Other treatment-
related adverse events that occurred with exposure 
to ttfC in pivotal studies included hair disorder 
(changes in eyelash), blurred vision, ocular pain, photo-
phobia and keratitis. from this group of ocular adverse 
events, we reported eyelashes growth in 2 patients (4 
eyes), according to expectations with treatment in the 
group of PgA antiglaucoma medications 13-18. we did 
not find any changes of iris color, although expected, 
most probably due to short time of follow up.
The low discontinuation rate after 6 months indi-
cates a good tolerability profile 28,29.
Conclusion
well designed observational studies can identify 
clinically important differences among therapeutical 
options and provide data on  drug effectiveness and 
safety.31 in our study iOP lowering effect ttfC was 
superior in comparison to previous monotherapy with 
betaxolol 0,5%, timolol 0,5%, latanoprost 0,005% and 
travoprost 0,004%, with statistically significant dif-
ferences in mean iOP after 30, 90 and 120 days of 
therapy. ttfC showed indurance of intraocular pres-
sure lowering effect in 6 month observational period.
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Sažetak
SigurnOSt i uČinKOvitOSt fiKSne KOmbinACiJe (trAvOPrOSt 0,004%/timOlOl 0,5%) 
umJeStO mOnOterAPiJe u ŠeStOmJeSeČnOm PeriOdu PrAĆenJA
Z.  mandić, K. novak-lauš, l. bojić, S. Popović-Suić, m. ekert , v. maričić došen, g. Pelčić, d. Clementi, d. 
dobutović, d. biuk, r. iveković, Ž. Kovačić, J. Pavan, n. Sušić, i. Krolo, A. Jurić-miletić, K. Kapeli dogan, 
m. tomić, S. Kovačević
CILJ: Zabilježiti sigurnost i učinkovitost promjene antiglaukomske terapije u travoprost 0,004%/timolol 0,5% (ttfC) 
fiksnu kombinaciju s prethodnih monoterapija.
METODE: Prospektivna, otvorena, opservacijska, multicentrična populacija. Promjena s prethodne monoterapije 
na dan 0 u ttfC, doziran jednom dnevno, ili ujutro ili navečer, bez perioda ispiranja. Aktivno je ocijenjena sistemska i 
lokalna podnošljivost (popratne pojave), i učinkovitost tj.sniženje intraokularnog tlaka (iOt) na prvoj kontroli (dan 30), 
drugoj kontroli (dan 90) i trećoj kontroli (dan 120). 
REZULTATI: 40/155/170 bolesnika (79/309/339 očiju) završilo je studiju (120 dana/ 90 dana/početak). na prvoj 
kontroli isključeni su svi bolesnici koji su slabo podnosili lijek: ozbiljna hiperemija (6 bolesnika), neugoda (4), bol u prsištu 
(1) i ne- responderi tj. sniženje iOt-a manje od 15% od početnog iOt ili ciljnog iOt >18 mmhg (4 bolesnika). 
Prosječni iOt na prvoj kontroli je bio 15,92±1,85 mm hg (21,66% sniženja) kod 155 bolesnika (isključeni ne-res-
ponderi), na drugoj kontroli je kod 155 bolesnika bio 15,67±2,17 mm hg (21,14% sniženja), i na trećoj kontroli kod 40 
bolesnika 16,28±1,59 mm hg (19,86% sniženja).
na drugoj kontroli je učinjena analiza sniženja iOt-a u 4 grupe prethodno korištene monoterapije: timolol 0,5% 
(n=33/66), latanoprost 0,005% (n=49/98), betaxolol 0,5% (n=30/60), i travoprost 0,004% (n=43/85). 
40 bolesnika/79 očiju praćeno je do treće kontrole. učinjena je analiza sniženja iOt-a u 4 grupe prethodno kori-
štene monoterapije: timolol 0,5% (n=7/14), latanoprost 0,005% (n=14/28), betaxolol 0,5% (n=7/14), travoprost 0,004% 
(n=12/23). 
Zaključak: Promjena terapije s prethodne monoterapije u ttfC može u prosjeku omogućiti dodatno sniženje iOt-a, 
uz zadovoljavajući profil sigurnosti.
Klučne riječi: Glaukom – terapija lijekovima; Očna hipertenzija – terapija lijekovima; Očni tlak – učinci lijekova; Antihiper-
tenzivni lijekovi – davanje i doziranje; Kombinacije lijekova

